Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic/Glioma Fusion Vaccine + IL-12 in GBM
NCT04388033Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell-tumor fusion vaccine in glioblastoma (GBM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Adverse Events / Serious Adverse Events and Progression Free Survival at 6 months. Status: unknown.
02
Drugs
autologous dendritic cell-tumor fusion vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04388033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388033.